Baclofen Treatment in the Criminal Law Context

While the debate about the efficacy of baclofen treatment for alcohol use disorder continues, the relevance of the treatment and underlying diagnosis of an anxiety disorder is important now in the context of criminal cases where there is a question as to the mental capacity of an accused to form the requisite intention to commit … Continue reading Baclofen Treatment in the Criminal Law Context

New Paper:The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective

The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective (click to read) Frontiers in Psychiatry has just published a new paper on baclofen in the treatment of alcoholism written by pre-eminent authorities on the subject.   The authors of the paper review the use of baclofen in treatment disorder and the … Continue reading New Paper:The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective

Open letter to Science Magazine regarding NIH investigation of George Koob

Dear Jocelyn, Earlier, I sent you an email with some links to my involvement in baclofen treatment for alcoholism. What prompted me to write to you was your article about George Koob being investigated in relation to his stopping funding policy studies. I've been following baclofen studies for the past 9 years. Baclofen was first … Continue reading Open letter to Science Magazine regarding NIH investigation of George Koob

Baclofen user takes French ANSM to court

   The French society for safety in medicines decided unilaterally to reduce the permissible dosage of baclofen to 80 mg last year.  It advised doctors and pharmacists not to issue prescriptions for high dose baclofen because, it said, there was evidence of hospital admissions and suicides or attempts by users of high dose baclofen.  This … Continue reading Baclofen user takes French ANSM to court

Baclofen Now a First Line Treatment -French RTU extended – New Modalities of Treatment

In March 2014, the National Agency for the Safety of Medicines and Health Products (ANSM) developed, for a period of 3 years, a Temporary Use Recommendation (RTU) for baclofen in the management of alcohol- dependent. Pending the results of the CNAMTS-ANSM study on safety, and the final reports of the two clinical studies, Alpadir and … Continue reading Baclofen Now a First Line Treatment -French RTU extended – New Modalities of Treatment